2022
The importance of an early onset of migraine prevention: an evidence-based, hypothesis-driven scoping literature review
Gottschalk C, Buse DC, Marmura MJ, Torphy B, Pavlovic JM, Dumas PK, Lalvani N, Blumenfeld A. The importance of an early onset of migraine prevention: an evidence-based, hypothesis-driven scoping literature review. Therapeutic Advances In Neurological Disorders 2022, 15: 17562864221095902. PMID: 35662957, PMCID: PMC9160905, DOI: 10.1177/17562864221095902.Peer-Reviewed Original ResearchMigraine preventionEarly onsetDay 1Migraine daysAvailable clinical trial evidenceAnti-CGRP monoclonal antibodiesFirst treatment weekMigraine preventive therapyMigraine preventive treatmentTraditional oral agentsWeekly migraine daysClinical trial evidenceLeast moderate severityPatient-level outcomesRelevant benefitsOnset preventionOral agentsPreventive therapyChronic migraineMigraine frequencyTrial evidenceTreatment weekPreventive treatmentModerate severityPreventive benefits
2020
Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin
Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Lindsey H, Pittman BP, Cozzi NV, D'Souza D. Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. Neurotherapeutics 2020, 18: 534-543. PMID: 33184743, PMCID: PMC8116458, DOI: 10.1007/s13311-020-00962-y.Peer-Reviewed Original ResearchConceptsTherapeutic effectAdverse eventsSingle administrationPsychotropic effectsWeekly migraine daysSerious adverse eventsCross-over studyEffects of psilocybinOral placeboMigraine daysMigraine frequencyClinical effectsControlled StudyHeadache disordersMigraine headacheHeadache diaryDrug effectsDrug AdministrationNeuropsychiatric conditionsMigraineFinal analysisStudy proceduresReceptor ligandsWeeksAdministration